Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View


Bausch Health Companies Inc BHC has reported Q4 revenues of $2.19 billion, down 1% Y/Y, missing the consensus of $2.80 billion.

  • Excluding the impact of foreign exchange, divestitures & discontinuations, revenue was flat organically.
  • Adjusted net income declined to $463 million from $478 million.
  • Adjusted EBITDA reached $909 million, as compared to $911 million.
  • Bausch Pharma revenues were $1.195 billion for Q4 FY21, down 6% Y/Y. Excluding the unfavorable impact of foreign exchange of $6 million and the impact of divestitures and discontinuations of $70 million, revenue was flat organically.
  • Also See: Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO.
  • Operating income was $367 million as compared to a loss of $(5) million a year ago, primarily driven by lower Other expense and lower loss on assets held for sale and amortization, partially offset higher SG&A expenses primarily due to an increase in separation, separation-related, IPO and IPO-related costs.
  • The Company generated $24 million of cash from operations in Q4 FY21.
  • Bausch Health reported GAAP EPS of $0.19, a turnaround from a $(0.43) loss a year ago.
  • Guidance: For FY22, Bausch Health expects sales of $8.40 billion – $8.60 billion, compared to the consensus of $8.75 billion.
  • The Company forecasts adjusted EBITDA of $3.45 billion – $3.60 billion.
  • Price Action: BHC shares are 0.23% at $23.55 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!